Skip to main content
Premium Trial:

Request an Annual Quote

Jonathan Blackburn, Thomas Gerson, Concetta Bartosh, Elias Caro, George Bers, Ed Vivanco, Peter Ringrose

Premium

Following the acquisition of Sense Proteomic, based in Cambridge, UK, by Procognia of Maidenhead, UK, Jonathan Blackburn, formerly CSO of Sense Proteomic, will become Procognia's chief scientist.

Thomas Gerson, vice president of finance and operations, has been promoted to CFO of Cellular Genomics of Branford, Conn. Prior to joining CGI, Gerson was director of financial planning and analysis at Sanofi Pharmaceuticals' US R&D operations. Gerson holds a BA from Boston College and an MBA from the University of Chicago. Mark Velleca, vice president of research, has been promoted to the newly created position of vice president of research and preclinical development. He holds an MD and PhD in neurosciences from Washington University.

Concetta Bartosh has become vice president for legal affairs at Gaithersburg, Md.-based Panacea Pharmaceuticals. She joins the company from the National Heart, Lung, and Blood Institute, where she was director of the office of technology transfer and development. She holds a JD from the Cleveland-Marshall College of Law at Cleveland State University.

Elias Caro has become president of the new biomedical research division of Beckman Coulter, based in Fullerton, Calif. This division consolidates the life science research and specialty testing divisions. Caro has been with Beckman since 1985, and holds a master's degree in polymer science from the University of Akron in Akron, Ohio, and an MBA and a bachelor's degree in industrial engineering from the Universidad de los Andes in Bogota, Colombia. George Bers, president of the former life science research division, has become vice president of systems biology, a new position created to strengthen the company' s presence in genomics, proteomics, and cellomics research. Ed Vivanco, president of the former specialty testing division, has become vice president of operations.

Peter Ringrose has been appointed non-executive director of the board of Cambridge Antibody Technology of Cambridge, UK. Until last month, Ringrose was CSO and president of Bristol-Myers Squibb Research Institute in Princeton, N.J., and a member of the executive committee of Bristol-Myers Squibb. He holds a PhD in microbial biochemistry from Cambridge University.